Pharmacokinetic modeling to determine the minimum effective dose of disease-specific antibodies for preventing hepatitis A post-exposure.

MLA

Young, Megan K., et al. “Pharmacokinetic Modeling to Determine the Minimum Effective Dose of Disease-Specific Antibodies for Preventing Hepatitis A Post-Exposure.” Expert Opinion on Drug Metabolism & Toxicology, vol. 16, no. 7, July 2020, pp. 641–44. EBSCOhost, https://doi.org/10.1080/17425255.2020.1763303.

APA

Young, M. K., Ng, S.-K., Nimmo, G. R., & Cripps, A. W. (2020). Pharmacokinetic modeling to determine the minimum effective dose of disease-specific antibodies for preventing hepatitis A post-exposure. Expert Opinion on Drug Metabolism & Toxicology, 16(7), 641–644. https://doi.org/10.1080/17425255.2020.1763303

Chicago

Young, Megan K, Shu-Kay Ng, Graeme R Nimmo, and Allan W Cripps. 2020. “Pharmacokinetic Modeling to Determine the Minimum Effective Dose of Disease-Specific Antibodies for Preventing Hepatitis A Post-Exposure.” Expert Opinion on Drug Metabolism & Toxicology 16 (7): 641–44. doi:10.1080/17425255.2020.1763303.